Alawi A Alsheikh-Ali

Summary

Affiliation: Tufts Medical Center
Country: USA

Publications

  1. ncbi The relationship of statins to rhabdomyolysis, malignancy, and hepatic toxicity: evidence from clinical trials
    Alawi A Alsheikh-Ali
    Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, 800 Washington Street, Boston, MA 02111, USA
    Curr Atheroscler Rep 11:100-4. 2009
  2. ncbi Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system)
    Alawi A Alsheikh-Ali
    Molecular Cardiology Research Institute and Division of Cardiology, Tufts New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts, USA
    Am J Cardiol 99:379-81. 2007
  3. ncbi Adverse events with concomitant use of simvastatin or atorvastatin and thiazolidinediones
    Alawi A Alsheikh-Ali
    Department of Medicine, Division of Cardiology, Preventive Cardiology Center, Tufts New England Medical Center, 750 Washington Street, Boston, MA 02111, USA
    Am J Cardiol 93:1417-8, A9. 2004
  4. ncbi Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use
    Noa Holoshitz
    Molecular Cardiology Research Institute and Division of Cardiology, Department of Medicine, Tufts New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts, USA
    Am J Cardiol 101:95-7. 2008
  5. ncbi Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials
    Alawi A Alsheikh-Ali
    Molecular Cardiology Research Institute and Division of Cardiology, Department of Medicine, Tufts New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts 02111, USA
    J Am Coll Cardiol 50:409-18. 2007
  6. doi Baseline and on-treatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipid-altering therapy
    Haseeb Jafri
    Molecular Cardiology Research Institute, Department of Medicine, Tufts Medical Center and Tufts University School of Medicine, Boston, Massachusetts 02111, USA
    J Am Coll Cardiol 55:2846-54. 2010
  7. ncbi Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol
    Alawi A Alsheikh-Ali
    Division of Cardiology and Molecular Cardiology Research Institute, Department of Medicine, Tufts New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts, USA
    Am J Cardiol 100:1499-501. 2007
  8. ncbi Adverse events with concomitant amiodarone and statin therapy
    Alawi A Alsheikh-Ali
    Department of Medicine, Division of Cardiology, Preventive Cardiology Center, Tufts New England Medical Center, Boston, MA 02111, USA
    Prev Cardiol 8:95-7. 2005
  9. ncbi Comparison of the frequency of adverse events in patients treated with atorvastatin or simvastatin
    Heather M Abourjaily
    Department of Pharmacy, Tufts New England Medical Center, 750 Washington Street, Boston, MA 02111, USA
    Am J Cardiol 91:999-1002, A7. 2003
  10. doi 3D echocardiography to evaluate right atrial pressure in acutely decompensated heart failure correlation with invasive hemodynamics
    Ayan R Patel
    Cardiovascular Imaging and Hemodynamic Laboratory, Tufts Medical Center, Boston, Massachusetts 02111, USA
    JACC Cardiovasc Imaging 4:938-45. 2011

Collaborators

Detail Information

Publications30

  1. ncbi The relationship of statins to rhabdomyolysis, malignancy, and hepatic toxicity: evidence from clinical trials
    Alawi A Alsheikh-Ali
    Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, 800 Washington Street, Boston, MA 02111, USA
    Curr Atheroscler Rep 11:100-4. 2009
    ....
  2. ncbi Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system)
    Alawi A Alsheikh-Ali
    Molecular Cardiology Research Institute and Division of Cardiology, Tufts New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts, USA
    Am J Cardiol 99:379-81. 2007
    ....
  3. ncbi Adverse events with concomitant use of simvastatin or atorvastatin and thiazolidinediones
    Alawi A Alsheikh-Ali
    Department of Medicine, Division of Cardiology, Preventive Cardiology Center, Tufts New England Medical Center, 750 Washington Street, Boston, MA 02111, USA
    Am J Cardiol 93:1417-8, A9. 2004
    ..1 times more likely to list rosiglitazone or pioglitazone as a concomitant medication compared with simvastatin-associated adverse event reports...
  4. ncbi Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use
    Noa Holoshitz
    Molecular Cardiology Research Institute and Division of Cardiology, Department of Medicine, Tufts New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts, USA
    Am J Cardiol 101:95-7. 2008
    ..Rates of all AERs and serious AERs were higher with fenofibrate, but well within the range observed with commonly used lipid-altering medications...
  5. ncbi Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials
    Alawi A Alsheikh-Ali
    Molecular Cardiology Research Institute and Division of Cardiology, Department of Medicine, Tufts New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts 02111, USA
    J Am Coll Cardiol 50:409-18. 2007
    ..We sought to assess the relationship between the magnitude of low-density lipoprotein cholesterol (LDL-C) lowering and rates of elevated liver enzymes, rhabdomyolysis, and cancer...
  6. doi Baseline and on-treatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipid-altering therapy
    Haseeb Jafri
    Molecular Cardiology Research Institute, Department of Medicine, Tufts Medical Center and Tufts University School of Medicine, Boston, Massachusetts 02111, USA
    J Am Coll Cardiol 55:2846-54. 2010
    ..We sought to examine the relationship between high-density lipoprotein cholesterol (HDL-C) levels and the risk of the development of cancer in large randomized controlled trials (RCTs) of lipid-altering interventions...
  7. ncbi Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol
    Alawi A Alsheikh-Ali
    Division of Cardiology and Molecular Cardiology Research Institute, Department of Medicine, Tufts New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts, USA
    Am J Cardiol 100:1499-501. 2007
    ..In conclusion, in high-risk patients with CHD or CHD risk equivalents, low HDL cholesterol levels remain prevalent despite statin treatment and the achievement of aggressive LDL cholesterol goals...
  8. ncbi Adverse events with concomitant amiodarone and statin therapy
    Alawi A Alsheikh-Ali
    Department of Medicine, Division of Cardiology, Preventive Cardiology Center, Tufts New England Medical Center, Boston, MA 02111, USA
    Prev Cardiol 8:95-7. 2005
    ..Use of a statin not metabolized through the cytochrome P450-3A4 system may be appropriate in this setting...
  9. ncbi Comparison of the frequency of adverse events in patients treated with atorvastatin or simvastatin
    Heather M Abourjaily
    Department of Pharmacy, Tufts New England Medical Center, 750 Washington Street, Boston, MA 02111, USA
    Am J Cardiol 91:999-1002, A7. 2003
  10. doi 3D echocardiography to evaluate right atrial pressure in acutely decompensated heart failure correlation with invasive hemodynamics
    Ayan R Patel
    Cardiovascular Imaging and Hemodynamic Laboratory, Tufts Medical Center, Boston, Massachusetts 02111, USA
    JACC Cardiovasc Imaging 4:938-45. 2011
    ....
  11. doi The safety of niacin in the US Food and Drug Administration adverse event reporting database
    Alawi A Alsheikh-Ali
    Institute for Clinical Research and Health Policy Studies and Molecular Cardiology Research Institute, Department of Medicine, Tufts New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts 02111, USA
    Am J Cardiol 101:9B-13B. 2008
    ..These analyses should encourage the use of niacin-ER in patients at high risk for cardiovascular disease, as recommended by current national guidelines for cardiovascular prevention...
  12. doi Statins, low-density lipoprotein cholesterol, and risk of cancer
    Alawi A Alsheikh-Ali
    Institute for Clinical Research and Health Policy Studies, Department of Medicine, Tufts Medical Center and Tufts University School of Medicine, Boston, Massachusetts 02111, USA
    J Am Coll Cardiol 52:1141-7. 2008
    ..We sought to assess whether statin-mediated reductions in low-density lipoprotein cholesterol (LDL-C) are associated with an increased risk of cancer...
  13. doi Reduced diameter spheres increases the risk of chest blow-induced ventricular fibrillation (commotio cordis)
    John Kalin
    Cardiac Arrhythmia Center, Division of Cardiology, Tufts Medical Center, Boston, Massachusetts, USA
    Heart Rhythm 8:1578-81. 2011
    ..However, the risk of ventricular fibrillation (VF) relative to the shape of the impact object is not known...
  14. doi The vulnerable atherosclerotic plaque: scope of the literature
    Alawi A Alsheikh-Ali
    Institute for Clinical Research and Health Policy Studies, Tufts University School of Medicine, Boston, MA, USA
    Ann Intern Med 153:387-95. 2010
    ..Large prospective studies in patients with and without previous cardiovascular events during long follow-up are required to validate this concept...
  15. doi Risk of arrhythmic and nonarrhythmic death in patients with heart failure and chronic kidney disease
    Alawi A Alsheikh-Ali
    Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA
    Am Heart J 161:204-209.e1. 2011
    ....
  16. ncbi Extended-release niacin reduces LDL particle number without changing total LDL cholesterol in patients with stable CAD
    Haseeb Jafri
    Division of Cardiology, Tufts Medical Center and Tufts University School of Medicine, 800 Washington Street, Box 315, Boston, MA 02111 USA
    J Clin Lipidol 3:45-50. 2009
    ..The effects of extended-release niacin (ERN) on LDL particle numbers have not been studied...
  17. doi Pre-operative left atrial mechanical function predicts risk of atrial fibrillation following cardiac surgery
    Jessica A Haffajee
    Cardiovascular Imaging and Hemodynamic Laboratory, Tufts Medical Center, Boston, Massachusetts 02111, USA
    JACC Cardiovasc Imaging 4:833-40. 2011
    ....
  18. ncbi Extent to which accepted serum lipid goals are achieved in a contemporary general medical population with coronary heart disease risk equivalents
    Alawi A Alsheikh-Ali
    Division of Cardiology and Molecular Cardiology Research Institute, Tufts New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts, USA
    Am J Cardiol 98:1231-3. 2006
    ..5% were taking fibrates and 8.2% niacin. In conclusion, the present analysis highlights the dramatic need to further improve preventive measures in a substantial proportion of high-risk patients with CHD risk equivalents...
  19. doi Marked variability in susceptibility to ventricular fibrillation in an experimental commotio cordis model
    Alawi A Alsheikh-Ali
    Cardiac Arrhythmia Center, Division of Cardiology, Tufts Medical Center, 800 Washington St, Box 197, Boston, MA 02111, USA
    Circulation 122:2499-504. 2010
    ..Using our model of commotio cordis, we evaluated individual animal susceptibility to VF induction and assessed animal characteristics that might be involved...
  20. ncbi High-density lipoprotein cholesterol in the cardiovascular equation: does the "good" still count?
    Alawi A Alsheikh-Ali
    Molecular Cardiology Research Institute, Division of Cardiology, Tufts New England Medical Center, Tufts University School of Medicine, 750 Washington Street, Box 80, Boston, MA 02111, USA
    Atherosclerosis 180:217-23. 2005
    ....
  21. ncbi The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis
    Alawi A Alsheikh-Ali
    Molecular Cardiology Research Institute, Department of Medicine, Tufts New England Medical Center, 750 Washington St, Boston, MA 02111, USA
    Circulation 111:3051-7. 2005
    ..Controversial concerns about the safety of the newly marketed statin rosuvastatin have been raised on the basis of premarketing studies and a few postmarketing reports...
  22. doi Time-dependence of appropriate implantable defibrillator therapy in patients with ischemic cardiomyopathy
    Alawi A Alsheikh-Ali
    Institute for Clinical Research and Health Policy Studies, New England Cardiac Arrhythmia Center, Department of Medicine, Tufts New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts 02111, USA
    J Cardiovasc Electrophysiol 19:784-9. 2008
    ..We assessed the incidence and time-dependence of appropriate ICD therapy in a routine clinical practice primary prevention population with prior myocardial infarction (MI) and reduced left ventricular ejection fraction (LVEF)...
  23. doi Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk
    Haseeb Jafri
    Molecular Cardiology Research Institute, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, and Tufts University School of Medicine, Boston, Massachusetts 02111, USA
    Ann Intern Med 153:800-8. 2010
    ..Low levels of high-density lipoprotein cholesterol (HDL-C) are associated with an increased risk for myocardial infarction (MI). Although statins reduce the risk for MI, most cardiovascular events still occur despite statin treatment...
  24. ncbi Assessment of peripheral vascular endothelial function in the ambulatory setting
    Jeffrey T Kuvin
    Department of Medicine Division of Cardiology, Tufts New England Medical Center, Boston, Massachusetts 02111, USA
    Vasc Med 12:13-6. 2007
    ..In conclusion, these data suggest that peripheral vascular endothelial function testing is feasible in ambulatory patients, and this is an important next step in bringing this technology to clinical applicability...
  25. ncbi Risk of adverse events with fibrates
    Alawi A Alsheikh-Ali
    Molecular Cardiology Research Institute, Department of Medicine, Division of Cardiology, Tufts New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts 02111, USA
    Am J Cardiol 94:935-8. 2004
    ..This difference was especially noticeable in patients taking the combination of gemfibrozil and a statin, particularly cerivastatin...
  26. doi Precordial thump for cardiac arrest is effective for asystole but not for ventricular fibrillation
    Christopher Madias
    Cardiac Arrhythmia Center, Division of Cardiology, Tufts Medical Center, Boston, MA 02111, USA
    Heart Rhythm 6:1495-500. 2009
    ..e., commotio cordis), they paradoxically have been regarded as potential therapy for cardiac arrest. In commotio cordis, impact energy and resultant peak left ventricular (LV) pressure are important variables in VF initiation...
  27. ncbi Risk of adverse events with concomitant use of atorvastatin or simvastatin and glucose-lowering drugs (thiazolidinediones, metformin, sulfonylurea, insulin, and acarbose)
    Alawi A Alsheikh-Ali
    Department of Medicine, Division of Cardiology, Preventive Cardiology Center, Boston, Massachusetts 02111, USA
    Am J Cardiol 89:1308-10. 2002
  28. doi Predictors of atrial fibrillation recurrence after radiofrequency catheter ablation: a systematic review
    Ethan M Balk
    Tufts Evidence based Practice Center, TuftsMedical Center, Boston, Massachusetts, USA
    J Cardiovasc Electrophysiol 21:1208-16. 2010
    ..AF Recurrence After RFA: Systematic Review...
  29. ncbi Ezetimibe, and the combination of ezetimibe/simvastatin, and risk of cancer: A post-marketing analysis
    Alawi A Alsheikh-Ali
    Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, 800 Washington St, Box 80, Boston, MA 02111USA Molecular Cardiology Research Institute, Department of Medicine, Tufts Medical Center and Tufts University School of Medicine, 800 Washington St, Boston, MA 02111USA
    J Clin Lipidol 3:138-42. 2009
    ....
  30. pmc Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20-year synopsis and a network meta-analysis
    Thomas A Trikalinos
    Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA
    Lancet 373:911-8. 2009
    ..We undertook a systematic overview of randomised trials comparing these interventions with each other and with medical therapy in patients with non-acute coronary artery disease...